Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 14, 2022

SELL
$1.35 - $2.88 $135 - $288
-100 Reduced 4.76%
2,000 $4,000
Q3 2021

Oct 26, 2021

SELL
$4.83 - $7.2 $6,762 - $10,080
-1,400 Reduced 40.0%
2,100 $12,000
Q2 2021

Jul 19, 2021

BUY
$2.32 - $5.38 $8,119 - $18,830
3,500 New
3,500 $17,000
Q3 2020

Oct 27, 2020

SELL
$1.45 - $2.0 $1,885 - $2,600
-1,300 Closed
0 $0
Q4 2018

Feb 05, 2019

BUY
$1.0 - $6.12 $1,300 - $7,956
1,300 New
1,300 $1,000
Q3 2018

Nov 07, 2018

SELL
$6.03 - $11.24 $39,195 - $73,060
-6,500 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$8.91 - $14.54 $49,896 - $81,424
5,600 Added 622.22%
6,500 $69,000
Q1 2018

May 11, 2018

BUY
$5.57 - $14.28 $5,013 - $12,852
900 New
900 $9,000

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $64.4M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.